To the editor:

Abelson murine leukemia viral oncogene homolog (ABL) tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib have improved the survival of Philadelphia chromosome (Ph)-positive leukemia patients.1  However, despite the impressive efficacy of these agents, disease relapse has been frequently observed. Mutations in the breakpoint region cluster protein (BCR)-ABL kinase domain can cause ABL TKI-resistance.2  One particular BCR-ABL kinase domain mutation, T315I, is associated with a high level of resistance to all available ABL TKIs. Ponatinib (AP24534) is a multitarget TKI. Recently, in the Ponatinib Ph+ Acute Lymphocytic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) Evaluation (PACE) trial, ponatinib showed significant efficacy against Ph-positive leukemia in patients with multiresistant T315I mutations.3  However, in some patients, especially those with Ph-positive ALL, ponatinib-resistant clones were identified.

Omacetaxine mepesuccinate (OM), formally known as homoharringtonine, is a natural alkaloid obtained from various Cephalotaxus species. OM is a first-in-class cephalotaxine in clinical development as an antileukemic therapy. OM acts by binding to the A-site cleft of ribosomes, thereby transiently inhibiting protein synthesis. OM was approved for the treatment of adult patients with chronic- or accelerated-phase CML that was resistant to other therapies.4 

We investigated the efficacy of OM against ponatinib-resistant Ph-positive cells. Ba/F3 ponatinib-resistant (Ba/F3 ponatinib-R) cells have 3 BCR-ABL point mutations (Y253H, E255K, and T315I; data not shown). With 72 hours of OM treatment, the cell growth of Ba/F3 ponatinib-R and Ph-positive ALL cell lines was significantly reduced, even when treated with low concentrations of OM (Figure 1A and supplemental Figure 1A). This agent is also effective against other hematological malignancies such as acute myeloid leukemia.5  In contrast, Ba/F3 ponatinib-R cells were resistant to ponatinib (Figure 1B). With 48 hours of treatment, OM-dependent apoptosis was increased (Figure 1C). The resistance of Ba/F3 cells bearing these 3-point mutations to ponatinib is consistent with the high-level resistance conferred by compound mutations such as E255V/T315I,6,7  although Ba/F3 ponatinib-R cells did not display increased antiapoptotic proteins.

Figure 1

Effects of OM and ponatinib on BCR-ABL-expressing point mutant cells. (A) Ba/F3 T315I cells were cultured at a density of 5 × 106 cells with 50 μg/mL N-ethyl-N-nitrosourea for 24 hours and washed 3 times with RPMI medium. The cells were cultured in RPMI medium with ponatinib, and resistant clones were identified (Ba/F3 ponatinib-resistant [Ba/F3 ponatinib-R]). These Ba/F3 ponatinib-R cells were treated with OM for 72 hours. The number of viable cells was calculated for each group. Results from 3 independent experiments were averaged. *P < .05, OM treatment vs control. (B) Ba/F3 ponatinib-R cells were treated with ponatinib at the indicated concentrations for 72 hours. The number of viable cells was calculated for each group. Results from 3 independent experiments were averaged. (C) The percentage of apoptotic cells was estimated using an annexin V assay after culturing the cells for 48 hours with OM. Results from 3 independent experiments were averaged. Error bars represent standard deviations. *P < .05, OM treatment vs control in the same cell line. (D) Ba/F3 ponatinib-R cells were treated with OM or ponatinib for 48 hours. Total extracts were analyzed by immunoblotting with phospho-specific anti-Abl, Crk-L, cleaved caspase 3, cleaved PARP, Abl, Crk-L, HSP90, Bcl-2, and c-Myc antibodies. Actin was used as the loading control. Data are representative of 3 separate experiments. (E) Ponatinib-resistant Ph-positive primary cells were cultured at a density of 4 × 105 cells/well in the presence of ponatinib and OM for 72 hours. The number of viable cells was calculated for each group. Results from 3 independent experiments were averaged. *P < .05, OM treatment vs control in the same cell line.

Figure 1

Effects of OM and ponatinib on BCR-ABL-expressing point mutant cells. (A) Ba/F3 T315I cells were cultured at a density of 5 × 106 cells with 50 μg/mL N-ethyl-N-nitrosourea for 24 hours and washed 3 times with RPMI medium. The cells were cultured in RPMI medium with ponatinib, and resistant clones were identified (Ba/F3 ponatinib-resistant [Ba/F3 ponatinib-R]). These Ba/F3 ponatinib-R cells were treated with OM for 72 hours. The number of viable cells was calculated for each group. Results from 3 independent experiments were averaged. *P < .05, OM treatment vs control. (B) Ba/F3 ponatinib-R cells were treated with ponatinib at the indicated concentrations for 72 hours. The number of viable cells was calculated for each group. Results from 3 independent experiments were averaged. (C) The percentage of apoptotic cells was estimated using an annexin V assay after culturing the cells for 48 hours with OM. Results from 3 independent experiments were averaged. Error bars represent standard deviations. *P < .05, OM treatment vs control in the same cell line. (D) Ba/F3 ponatinib-R cells were treated with OM or ponatinib for 48 hours. Total extracts were analyzed by immunoblotting with phospho-specific anti-Abl, Crk-L, cleaved caspase 3, cleaved PARP, Abl, Crk-L, HSP90, Bcl-2, and c-Myc antibodies. Actin was used as the loading control. Data are representative of 3 separate experiments. (E) Ponatinib-resistant Ph-positive primary cells were cultured at a density of 4 × 105 cells/well in the presence of ponatinib and OM for 72 hours. The number of viable cells was calculated for each group. Results from 3 independent experiments were averaged. *P < .05, OM treatment vs control in the same cell line.

Close modal

We also examined intracellular signaling. The phosphorylation of BCR-ABL and a downstream molecule, v-Crk avian sarcoma virus CT10 oncogene homolog-like (Crk-L), were decreased (Figure 1D). Protein expression levels of BCR-ABL and Crk-L were also decreased. However, caspase 3 and cleaved Poly (adenosine 5'-diphosphate-ribose) polymerase (PARP) levels were significantly increased in low concentration (Figure 1D). In a previous study, OM was shown to induce apoptosis in leukemic cells because of a selective decrease in short-lived proteins.8,9  We found that OM treatment reduced the expression of BCR-ABL, as well as heat shock protein (HSP)90, which stabilizes the BCR-ABL protein. We also found that OM reduced the expression level of the antiapoptotic protein Bcl-2. The level of c-Myc expressed was also reduced. We then examined ponatinib-resistant primary Ph-positive ALL and chronic-phase CML samples. The ponatinib-resistant primary cells had several BCR-ABL point mutations (eg, Q252H, E255K/V, and T315I). We found that the growth of primary cells was not affected by ponatinib but was reduced after OM treatment. Similar signaling events occurred in OM-treated primary ALL cells (Figure 1E and supplemental Figure 1B-C). Next, we used the pan-caspase inhibitor Z-VAD-fmk for the inhibition of caspases. Z-VAD-fmk treatment inhibited OM-induced apoptosis but did not prevent the degradation of BCR-ABL, HSP90, and Bcl-2 in Ba/F3 ponatinib-R cells (supplemental Figure 1D). Thus, BCR-ABL, HSP90, and Bcl-2 downregulation was independent of caspase activity.

OM is an inhibitor of protein synthesis. Because OM inhibits the BCR-ABL, Bcl-2, and HSP90 pathways in BCR-ABL-positive leukemia cells by reducing the levels of these proteins, OM has antitumor activity and promotes apoptosis. Our findings suggest that OM may be beneficial in the treatment of leukemia patients with BCR-ABL mutant cells, helping in overcoming ponatinib resistance.

The online version of this article contains a data supplement.

Acknowledgments: This work was supported by a High-Tech Research Center Project for private universities, a matching fund subsidy from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), and by the University-Industry Joint Research Project for private universities, a matching fund subsidy from MEXT. This work was also supported by Grants-in-Aid for Scientific Research from MEXT.

Contribution: S.O., T.T., Y.T., and K.O. conceived and designed the experiments; S.O., S.K., and T.K. performed the experiments; and S.O., T.T., Y.T., S.K., T.K., and K.O. contributed reagents and wrote the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Seiichi Okabe, First Department of Internal Medicine, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan; e-mail: [email protected].

1
Breccia
 
M
Alimena
 
G
How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages.
Cancer Lett
2012
, vol. 
322
 
2
(pg. 
127
-
132
)
2
Ernst
 
T
Hochhaus
 
A
Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression.
Semin Oncol
2012
, vol. 
39
 
1
(pg. 
58
-
66
)
3
Cortes
 
JE
Kantarjian
 
H
Shah
 
NP
et al. 
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
N Engl J Med
2012
, vol. 
367
 
22
(pg. 
2075
-
2088
)
4
Cortes
 
J
Lipton
 
JH
Rea
 
D
et al. 
Omacetaxine 202 Study Group
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
Blood
2012
, vol. 
120
 
13
(pg. 
2573
-
2580
)
5
Yu
 
W
Mao
 
L
Qian
 
J
et al. 
Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
Ann Hematol
2013
, vol. 
92
 
8
(pg. 
1091
-
1100
)
6
Khorashad
 
JS
Kelley
 
TW
Szankasi
 
P
et al. 
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Blood
2013
, vol. 
121
 
3
(pg. 
489
-
498
)
7
O’Hare
 
T
Shakespeare
 
WC
Zhu
 
X
et al. 
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Cancer Cell
2009
, vol. 
16
 
5
(pg. 
401
-
412
)
8
Tang
 
R
Faussat
 
AM
Majdak
 
P
et al. 
Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells.
Mol Cancer Ther
2006
, vol. 
5
 
3
(pg. 
723
-
731
)
9
Robert
 
F
Carrier
 
M
Rawe
 
S
Chen
 
S
Lowe
 
S
Pelletier
 
J
Altering chemosensitivity by modulating translation elongation.
PLoS ONE
2009
, vol. 
4
 
5
pg. 
e5428
 
Sign in via your Institution